These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35139265)

  • 1. Effectiveness of Homologous or Heterologous Covid-19 Boosters in Veterans.
    Mayr FB; Talisa VB; Shaikh O; Yende S; Butt AA
    N Engl J Med; 2022 Apr; 386(14):1375-1377. PubMed ID: 35139265
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequential heterologous immunization with COVID-19 vaccines induces broader neutralizing responses against SARS-CoV-2 variants in comparison with homologous boosters.
    Shen X; Hao Y; Wang S; Li D; Ren L; Zhu M; Wang S; Li J; Tang W; Fu Y; Chen R; Liu Y; Shao Y
    Vaccine; 2023 Oct; 41(45):6645-6653. PubMed ID: 37770297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterologous and BNT162b2 boosters are more effective than non-mRNA homologous boosters for Omicron.
    Paternina-Caicedo A; Quevedo DS; Ríos DS; Moyano D; Alvis-Guzmán N; Alviz-Zakzuk NR; Salcedo F; Ramírez-Suarez J; Smith AD; De la Hoz-Restrepo F
    J Infect; 2024 Jun; 88(6):106165. PubMed ID: 38670269
    [No Abstract]   [Full Text] [Related]  

  • 4. Heterologous COVID-19 vaccination as a strategy to accelerate mass immunization.
    Klastrup V; Stærke NB; Søgaard OS
    Clin Microbiol Infect; 2022 Oct; 28(10):1316-1318. PubMed ID: 35843563
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting.
    Younes S; Nicolai E; Younes N; Pieri M; Bernardini S; Nizamuddin PB; Al-Sadeq DW; Daas HI; Ismail A; Yassine HM; Abu-Raddad LJ; Nasrallah GK
    Vaccine; 2024 Oct; 42(23):126042. PubMed ID: 38845303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Homologous and Heterologous Vaccine Boosters With COVID-19 Incidence and Severity in Singapore.
    Tan SHX; Pung R; Wang LF; Lye DC; Ong B; Cook AR; Tan KB
    JAMA; 2022 Mar; 327(12):1181-1182. PubMed ID: 35147657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Audio Interview: A New Look at Covid-19 Vaccine Boosters.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Oct; 385(17):e72. PubMed ID: 34670050
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Le Gars M; Sadoff J; Cárdenas V; Heerwegh D; Tesfaye F; Roey GV; Spicer C; Matias SS; Crayne O; Kamphuis T; Struyf F; Schuitemaker H; Douoguih M
    Vaccine; 2024 Jul; 42(19):3938-3952. PubMed ID: 38918103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covid-19 Vaccines - Immunity, Variants, Boosters.
    Barouch DH
    N Engl J Med; 2022 Sep; 387(11):1011-1020. PubMed ID: 36044620
    [No Abstract]   [Full Text] [Related]  

  • 10. Homologous and Heterologous Covid-19 Booster Vaccinations.
    Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE; Mulligan MJ; Brady RC; Frenck RW; Bäcker M; Kottkamp AC; Babu TM; Rajakumar K; Edupuganti S; Dobrzynski D; Coler RN; Posavad CM; Archer JI; Crandon S; Nayak SU; Szydlo D; Zemanek JA; Dominguez Islas CP; Brown ER; Suthar MS; McElrath MJ; McDermott AB; O'Connell SE; Montefiori DC; Eaton A; Neuzil KM; Stephens DS; Roberts PC; Beigel JH;
    N Engl J Med; 2022 Mar; 386(11):1046-1057. PubMed ID: 35081293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mix-and-Match COVID-19 Boosters After Inactivated Virus Vaccine.
    Larkin HD
    JAMA; 2022 Jul; 328(3):234. PubMed ID: 35852521
    [No Abstract]   [Full Text] [Related]  

  • 12. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
    Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
    Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.
    Roa CC; de Los Reyes MRA; Plennevaux E; Smolenov I; Hu B; Gao F; Ilagan H; Ambrosino D; Siber G; Clemens R; Han HH
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301632. PubMed ID: 38206168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
    Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
    [No Abstract]   [Full Text] [Related]  

  • 15. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity After a Heterologous BNT262b2 Versus Homologous Booster in Kidney Transplant Recipients Receiving 2 Doses of CoronaVac Vaccine: A Prospective Cohort Study.
    Medina-Pestana J; Almeida Viana L; Nakamura MR; Lucena EF; Granato CFH; Dreige YC; Amorim LVP; Chow CYZ; Demarchi Foresto R; Roberto Requião-Moura L; Tedesco-Silva H; Cristelli MP
    Transplantation; 2022 Oct; 106(10):2076-2084. PubMed ID: 35939382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron.
    Accorsi EK; Britton A; Shang N; Fleming-Dutra KE; Link-Gelles R; Smith ZR; Derado G; Miller J; Schrag SJ; Verani JR
    N Engl J Med; 2022 Jun; 386(25):2433-2435. PubMed ID: 35613039
    [No Abstract]   [Full Text] [Related]  

  • 18. Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
    Rubin EJ; Baden LR; Morrissey S
    N Engl J Med; 2021 Sep; 385(12):e48. PubMed ID: 34525292
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2.
    Cohen CA; Leung NHL; Kaewpreedee P; Lee KWK; Jia JZ; Cheung AWL; Cheng SMS; Mori M; Ip DKM; Poon LLM; Peiris JSM; Cowling BJ; Valkenburg SA
    Nat Commun; 2024 Aug; 15(1):7358. PubMed ID: 39191745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2.
    Tenbusch M; Schumacher S; Vogel E; Priller A; Held J; Steininger P; Beileke S; Irrgang P; Brockhoff R; Salmanton-García J; Tinnefeld K; Mijocevic H; Schober K; Bogdan C; Yazici S; Knolle P; Cornely OA; Überla K; Protzer U;
    Lancet Infect Dis; 2021 Sep; 21(9):1212-1213. PubMed ID: 34332707
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.